Afatinib Withdrawn Phase 2 Trials for Her-2 Positive Gastric Cancer / Esophageal Cancers / Gastrooesophageal Cancer Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02274012Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment